Benzinga | Jan 25, 2022 07:35AM EST

Oppenheimer Maintains Outperform on Fulgent Genetics, Lowers Price Target to $125

Oppenheimer analyst Kevin DeGeeter maintains Fulgent Genetics (NASDAQ:FLGT) with a Outperform and lowers the price target from $141 to $125.